Skip to main content

Table 1 Individual tumor characteristics, mutation, and CGH analyses

From: Recurrent and multiple bladder tumors show conserved expression profiles

Tumor1

mtr2

Stage/grade3

FGFR3mut4,5

TP53mut4

Imbalances6

01.I

 

TaG2

  

dim (8p., 22p, 22q11–13.1)

     

enh (8q11–q22, Xq)

01.R1

5

TaG2

  

dim (8p)

     

enh (8q)

02.I

 

T2G3

  

dim (19p)

     

enh (1p31–p32, 1q23–q25, 8q, 12q13–q21)

02.R1

7

T2G3

  

enh (1q23–q24, 2p14-pter, 3p22-pter)

07.I

 

TaG1

S249C

 

na

07.R1

7

TaG2

S249C

K132N

na

09.I

 

T1G3

 

G245D

dim (2q33-qter, 6q24-qter, 9, 10q, 11p15-pter, 17, 22)

     

enh (1p11–p21, 1q11–q31, 2q11, 2q23–q24, 3, 8q11–q22, 11q14-qter, 16p, 16q11–q13, 18p, 20, X)

09.R1

10

TIG3

 

G245D

dim (9)

     

enh (1q22–q31, 2p13-pter, 3, 8, 16p, 16q11–q13, 20)

10.I

 

T1G2

S249C

R280T

dim (9q)

     

enh (12q13–q21)

10.R1

5

T1G3

S249C

R280T

dim (9q22-qter, 10q24-qter)

     

enh (10q21–q23, 20q, Xp, Xq11–q24)

13.I

 

T1G2

  

dim (9q, 10p12–p13, 16p, 17p, 19, 22)

     

enh (1p11–p31, 1q11–q41, 3, 5q14–q23, 8q13-qter, 12q15–q22, 13, 18q, 20p, X)

13.R1

6

T0

  

dim (4, 9, 17p, 19)

     

enh (1q23-qter, 3, 5q13–q23, 13, 14, 17q, 18q, 20, X)

14.I

 

T1G2

  

dim (8p, 9, 10p, 17p)

     

enh (8q)

14.R1

8

T1G3

  

dim (9, 10p, 19)

     

enh (8q)

16.I

 

TIG3

  

dim (8q)

     

enh (8p, 19)

16.R1

4

T1G2

  

dim (8q)

18.I

 

T1G2

  

dim (8p)

     

enh (1p32-pter, 1p13–p21, 1q21–q31, 1q33–q35, 3, 5p, 6p11–p22, 8q21-qter, 10q11–q23, 13q22-qter)

18.R1

16

T2G3

 

R273L

enh (3, 8q11–q23, 9p)

21.I

 

TaG2

  

dim (9q22-qter, 11p13-qter, 22)

     

enh (12p11–p12, 12q11–q23)

21.R1

7

T1G2

  

dim (8p, 9q, 10p, 11p, 11q11–q13.1, 12q24-qter, 16p, 17, 18p, 19, 22)

     

enh (3, 4p11–p15, 4q11–q32, 5q21–q23, 6q11–q14, 8q, 12q15–q21, 13q14-qter, 18q11–q22)

29.I

 

TaG2

S249C

 

dim (9q32-qter, 14q23-qter, 19)

     

enh (1q22-qter, 8q)

29.R1

21

TaG2

S249C

 

dim (9q22-qter)

     

enh (1q11–q31, 13, X)

30.I

 

TaG2

  

na

30.R1

13

TaG2

  

na

31.I

 

TaG2

 

R290H

na

31.R1

10

TaG2

  

na

31.R2

17

TaG2

  

dim (2q34-qter, 8p, 14, 19p)

     

enh (1q21-qter, 2p13-pter, 5p13-pter, 8q, 11q14–q24)

31.R3

19

T4G3

  

dim (2q31–q34, 5q11–q23, 6q, 9p12-pter)

     

enh (1q23–q24, 1q32-qter, 2p, 2q11–q14, 5p, 8)

34.I

 

T1G3

S249C

 

dim (9, 11p11-pter, 12p)

     

enh (1p31–p32, 1q23–q41)

34.R1

6

T2G3

S249C

 

dim (8p, 9)

     

enh (8q)

38.I

 

T1G3

 

R248Q

dim (9)

38.R1

9

T2G3

 

R248Q

na

38.R2

24

T2G3

 

R248Q

dim (19p)

     

enh (2q14–q21, 8q22-qter)

42.I

 

TaG2

S249C

 

dim (5q, 10q11–q21, 10q23-qter, 13p, 13q11–q14, 15, 17p, 18q, 19p)

     

enh (2p13-pter, 3, 5p, 6p22-pter, 8q13-qter, 9p22.1-pter, 12q14–q21.2, 18p, X)

42.R1

31

TaG1

S249C

 

enh (1q24-qter, 8q21–q23)

43.I

 

TaG1

S249C

 

na

43.R1

4

TaG1

Y375C

 

na

47.I

 

TaG2

  

na

47.R1

5

TaG2

  

na

47.R2

18

TaG1

  

na

53.I

 

TaG2

S249C

 

enh (X)

53.R1.S1

27

T1G2

S249C

 

dim (19p)

53.R1.S2

27

T1G2

S249C

 

dim (19p)

     

enh (Xp11-pter, Xq26-qter)

54.S1

-

T1G3

  

enh (1q23)

54.S2

-

T1G3

  

enh (8q21-qter, 12, 13)

56.S1

-

T2G3

  

dim (2q32.2-qter, 5q, 15, 16q)

     

enh (1p, 1q12–q23, 3, 5p, 8q, 13q21-qter, 16p, 17q, 20, 21, Xp22-pter)

56.S2

-

T2G3

 

Q331STOP

dim (8p)

     

enh (1, 2p, 2q11–q21, 3, 5p, 6p12-pter, 6q21–q23, 7p, 7q32-qter, 8q, 10p, 15q21-qter, 20)

64.S1

-

T3G3

na

na

na

64.S2

-

T3G3

na

na

na

  1. 1I, Initial tumor, i.e. the first resected tumor from a given patient; R, recurrent tumor; S, synchronous tumor.
  2. 2mtr, months to recurrence
  3. 3Histopathological staging and grading were reviewed according to the 2002 TNM and 1999 WHO classification systems by one single pathologist (GC)
  4. 4 Direct sequencing of exons 7, 10, and 15 of FGFR3 and exons 4 to 9 of TP53 was performed using BigDye terminator chemistry (Applied Biosystems, Foster City, CA). na, data not available either due no PCR products for sequencing or DNA quality unsuitable for CGH.
  5. 5FGFR3 amino acid positions are given according to the FGFR3 IIIb open reading frame; n/a, sequence data not available.
  6. 6Partial chromosomal losses in initial tumors incompatible with imbalances present in recurring tumors are in bold